EA202092223A1 - Разделение vwf и пропептида vwf хроматографическими методами - Google Patents

Разделение vwf и пропептида vwf хроматографическими методами

Info

Publication number
EA202092223A1
EA202092223A1 EA202092223A EA202092223A EA202092223A1 EA 202092223 A1 EA202092223 A1 EA 202092223A1 EA 202092223 A EA202092223 A EA 202092223A EA 202092223 A EA202092223 A EA 202092223A EA 202092223 A1 EA202092223 A1 EA 202092223A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vwf
mat
propeptide
separation
chromatographic methods
Prior art date
Application number
EA202092223A
Other languages
English (en)
Inventor
Кристиан Фидлер
Майнхард Хасслахер
Криста Майер
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of EA202092223A1 publication Critical patent/EA202092223A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Данное изобретение относится к способу отделения зрелого фактора фон Виллебранда (mat-VWF) от пропептида фактора фон Виллебранда (VWF-PP) путем инкубации композиции, включающему индукцию диссоциации mat-VWF и VWF-PP путем разрушения нековалентно связанных mat-VWF и VWF-PP, при этом указанная диссоциация индуцируется путем (i) добавления по меньшей мере одного хелатирующего агента или (ii) увеличения pH до pH, равного по меньшей мере 7, с последующим сбором указанного mat-VWF для получения высокоочищенного зрелого лишенного пропептида VWF (mat-VWF).
EA202092223A 2018-03-21 2019-03-20 Разделение vwf и пропептида vwf хроматографическими методами EA202092223A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646109P 2018-03-21 2018-03-21
PCT/US2019/023269 WO2019183290A1 (en) 2018-03-21 2019-03-20 Separation of vwf and vwf propeptide by chromatographic methods

Publications (1)

Publication Number Publication Date
EA202092223A1 true EA202092223A1 (ru) 2021-02-10

Family

ID=66223800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092223A EA202092223A1 (ru) 2018-03-21 2019-03-20 Разделение vwf и пропептида vwf хроматографическими методами

Country Status (14)

Country Link
US (2) US10934340B2 (ru)
EP (1) EP3768697A1 (ru)
JP (2) JP2021519280A (ru)
KR (1) KR20200144547A (ru)
CN (1) CN112533940A (ru)
AU (1) AU2019240135A1 (ru)
BR (1) BR112020019057A2 (ru)
CA (1) CA3094644A1 (ru)
CO (1) CO2020013056A2 (ru)
EA (1) EA202092223A1 (ru)
IL (1) IL277464A (ru)
MX (1) MX2020009788A (ru)
SG (1) SG11202009213TA (ru)
WO (1) WO2019183290A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F
CN115698245A (zh) * 2020-01-27 2023-02-03 百时美施贵宝公司 等电聚焦样品基质

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1992006999A1 (en) 1990-10-17 1992-04-30 The Scripps Research Institute Therapeutic fragments of von willebrand factor
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6190609B1 (en) 1996-11-19 2001-02-20 Baxter International Inc. Methods and apparatus for inactivating contaminants in biological fluid
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2434035T3 (es) 2004-12-27 2013-12-13 Baxter International Inc. Conjugados de polímero-factor von Willebrand
PL2522717T3 (pl) 2006-01-04 2014-08-29 Baxalta Inc Pożywki do hodowli komórkowych wolne od oligopeptydów
US7559509B1 (en) 2007-02-12 2009-07-14 Thomas C. Taylor Large cryogenic tank logistics for in-space vehicles
WO2008143977A1 (en) * 2007-05-18 2008-11-27 Baxter International Inc. Method for producing mature vwf from vwf pro-peptide
CN105816858A (zh) * 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
AU2009307648C1 (en) 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
BR112012003802B1 (pt) 2009-08-20 2022-10-25 Takeda Pharmaceutical Company Limited Método para remover um vírus sem envelope lipídico de uma solução
WO2011073235A1 (en) * 2009-12-18 2011-06-23 Csl Ltd. Method of purifying polypeptides
JP5953502B2 (ja) 2010-07-08 2016-07-20 バクスアルタ ゲーエムベーハー 細胞培養による組換え型高分子量ｖＷＦ産生方法
MX352082B (es) 2010-12-15 2017-11-08 Baxalta Inc Inactivacion viral utilizando un metodo mejorado de solvente-detergente.
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
BR112018003127A2 (pt) * 2015-08-20 2018-09-25 Genentech Inc purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes

Also Published As

Publication number Publication date
US20220041693A1 (en) 2022-02-10
CA3094644A1 (en) 2019-09-26
EP3768697A1 (en) 2021-01-27
KR20200144547A (ko) 2020-12-29
SG11202009213TA (en) 2020-10-29
CN112533940A (zh) 2021-03-19
JP2021519280A (ja) 2021-08-10
WO2019183290A1 (en) 2019-09-26
US20190382467A1 (en) 2019-12-19
JP2024001136A (ja) 2024-01-09
BR112020019057A2 (pt) 2020-12-29
IL277464A (en) 2020-11-30
CO2020013056A2 (es) 2020-10-30
MX2020009788A (es) 2020-12-09
US10934340B2 (en) 2021-03-02
AU2019240135A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
EA202190983A1 (ru) Новое антитело к с-kit
EA201891974A1 (ru) Ингибиторы связывания белка wdr5 с белками
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA201592192A1 (ru) Способ очистки моноклональных антител
EA202191668A1 (ru) Гетероциклил пиридазин в качестве фунгицидных соединений
EA202092223A1 (ru) Разделение vwf и пропептида vwf хроматографическими методами
CY1124630T1 (el) Επιλεκτικη αναγωγη αντισωματων τροποποιημενης κυστεϊνης
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
NZ781138A (en) Anti-vegf protein compositions and methods for producing the same
PH12021550244A1 (en) Anti-btla antibody
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MD3697789T2 (ro) Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
MX2021012251A (es) Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).
NZ774126A (en) Spd-1 variant - fc fusion proteins
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2022006145A (es) Anticuerpos trem2 y usos de estos.
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
MX2022004569A (es) Anticuerpo humanizado y metodo para usar el mismo.
EA202192840A1 (ru) Способ получения соединений карбамоилоксиметилтриазолциклогексиловой кислоты
FR3099478B1 (fr) Procédé de traitement d’une composition comprenant de la vanilline naturelle
MX2020009851A (es) Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos.
EA201892231A1 (ru) Способ очистки белка